Regulation
Pharaoh’s CSF management system secures FDA breakthrough designation
Pharaoh Medical received FDA Breakthrough Device designation for its Neurapheresis CSF management system, designed to treat complications following aneurysmal subarachnoid hemorrhage. The designation accelerates FDA review and signals recognition of the device's potential to address an unmet clinical need in neurosurgical care.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network